Arizona Pharmacy Flash
Aug. 14, 2012

Pharmacists will be valuable in Medicaid overhaul
The News Star
With so many unmet health needs, we do not want to put our valuable pharmacy network in danger by failing to ensure that we keep our pharmacy businesses viable. Nor do we want to limit a patient's choice to a few select pharmacies that may require patients to travel long distances. For managed care to be successful, there must be a robust network of providers, and our patients must have access to high-quality care. More

Community Pharmacy Academy Conference Changes Ahead
Arizona Pharmacy Association
Community Pharmacy Academy Conference Changes Ahead: Are You Ready?
September 22, 2012
Crowne Plaza Phoenix Airport Hotel

To register for the event, please click here.More

PTCB Exam Prep Course
Arizona Pharmacy Association
PTCB Exam Prep Course Begins September 8, 2012.
Visit the Arizona Pharmacy Association website for complete information.More

HealthMap Vaccine Finder
Arizona Pharmacy Association
Flu season is rapidly approaching. HealthMap Vaccine Finder is here to help.

Read more. More

Save the Date!
Arizona Pharmacy Association
Managed Care Academy Conference October 20, 2012. Complete information coming soon! More

2012 NIOSH hazardous-drugs update contains surprises
American Society of Health-System Pharmacists
The National Institute for Occupational Safety and Health recently updated its list of hazardous drugs used in healthcare settings. Some of the additions to the list may surprise pharmacists, said Cynthia Reilly, director of ASHP's Practice Development Division and a member of the advisory panel that NIOSH consults about changes to the list. Reilly said her role on the panel is to explain how changes to the list may affect pharmacy practice. More

Joint Commission sounds alert on opioid risks in hospitals
American Society of Health-System Pharmacists
The recent issue of Sentinel Event Alert from the Joint Commission seeks to raise awareness about adverse events — especially respiratory depression and over sedation — associated with the use of opioid analgesics in inpatient settings. According to the alert, opioid-induced respiratory depression should always be considered a potential complication of opioid therapy in hospitalized patients.More

Disclosure not necessary for off-label drug use
Medical News Today
Off-label drug use occurs when a physician prescribes medication to treat a condition before that use has been approved by the Food and Drug Administration. In a newly published article in Mayo Clinic Proceedings, researchers pose and answer 10 questions about off-label drug use. "Since the Food and Drug Administration does not regulate the practice of medicine, off-label drug use has become very common," says lead author Dr. Christopher Wittich, internal medicine physician at Mayo Clinic.More

CDC no longer recommends oral cephalosporins for gonorrhea
Medscape News (free subscription required)
The U.S. Centers for Disease Control and Prevention no longer recommends oral cephalosporin treatment for gonococcal infections, according to their updated guidelines, reported in the recent issue of the Morbidity and Mortality Weekly Report. The new recommendations update the CDC's 2010 Sexually Transmitted Diseases Treatment Guidelines.More

RxAlly aims to fully integrate pharmacy into healthcare system
Drug Topics via Modern Medicine
In February 2012, RxAlly launched its Performance Network of more than 20,000 pharmacies with a mission to generate measurable improvements in patient health outcomes while reducing healthcare costs. It is well on its way to launching an integrated platform to accomplish this goal — connecting all these pharmacies' data and aggregating it in a systematic way to address the challenges of lack of adherence.More

Generic drug shortages show no signs of abating
Drug Topics via Modern Medicine
As of midsummer, it was not looking as if the ongoing problem of drug shortages would get much better anytime soon. "We are continuing to see large numbers of shortages, we are still seeing the shortages mainly concentrated in the sterile injectable type of drugs, and we are still seeing them mainly due to quality problems that have been occurring at some of the large manufacturers of those drugs," said Valerie Jensen, associate director of FDA's Drug Shortage Program.More

Does age change carbamazepine pharmacokinetics?
Pharmacy Times
Carbamazepine is the most frequently prescribed antiepileptic drug for elderly patients, despite data that indicates that elders tolerate the AEDs lamotrigine and gabapentin better. The pharmacokinetics of carbamazepine are complex, and several factors — absorption variability, protein binding, therapeutic index and enzyme induction — may contribute to altered pharmacokinetics as patients age.More

'My parrot ate my pain pills': Which suspicious behavior to investigate?
Medscape News (free subscription required)
Two patients show up in your office complaining of severe pain and requesting opioid painkillers. How can you distinguish between the one who's suffering from genuine pain and the one who's abusing or diverting the medication? Dr. Batya Swift Yasgur describes her situation in dealing with opioid-requesting patients and how to differentiate between those who need the medication and those who are just trying to get a "high."More

Court tells FDA: Don't delay on protecting people against antibiotic overuse in factory farms
In a recent decision, a federal court in New York ruled that the Food and Drug Administration cannot delay regulatory proceedings for penicillin and tetracyclines use in livestock — two kinds of antibiotics whose overuse in animals is reducing their effectiveness in treating sick people. More

FDA approves Mylan's lithium carbonate ER tablets
The U.S. Food and Drug Administration has approved Mylan Pharmaceuticals' Abbreviated New Drug Application for lithium carbonate extended-release tablets USP, 450 mg. This product is indicated for the treatment of manic episodes of manic depressive illness.More

FDA approves Lucentis for diabetic eye disorder
The Wall Street Journal
The U.S. Food and Drug Administration recently recommended wider approval of Roche Holding AG's eye drug, Lucentis. The agency approved the product to treat a condition called diabetic macular edema, which is related to diabetes, and is the leading cause of blindness among working-age Americans. More